ThromboembolismTESEONCT03855592
Registry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica"
An observational study of Thromboembolism and Cancer, run by Fundación Sociedad Española de Oncologia Médica at 48 sites in Spain.
Trial summary
Epidemiological, observational, non-interventional, multicentric study on patients diagnosed with cancer who develop a venous or arterial thromboembolic episode, symptomatic or incidental, within a month prior to cancer diagnosis or at anytime after such diagnosis Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Thromboembolism, Cancer
- How many people
- 700 participants
- Where
- 48 sitesSpain
- Study dates
- 4 Jul 2018to Jul 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Cancer patients
Who may be able to join
- Over 18 years of age with a histologically confirmed diagnosis of malignant tumor.
- Venous or arterial thromboembolism episode, symptomatic or incidental, in the month prior or any time after the cancer diagnosis and in the three previous months to enrollment, confirmed with an imaging technique: Doppler echocardiography, computed tomography (CT) angiography, etc.
- Signing of informed consent.
Who cannot join
- Clinical diagnosis of thromboembolic event without radiological confirmation.
- Presenting a single episode of superficial thrombophlebitis without association with another thromboembolic event.
- Each patient will be recorded just once, and therefore a second thromboembolic event will be considered a rethrombosis and will be recorded as such. Patients with a rethrombosis and a previous thromboembolic event before the start of the study in each center will not be able to be included.
Trial locations and contacts
48 sites in 1 country. Contact the study team or a site near you to ask about taking part.
48 sites in 1 country
Spain48 sites, 48 recruiting
- Recruiting
Complejo Hospitalario Universitario de A Coruña
A Coruña
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Virgen de los Lirios
Alcoy, Alicante
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario San Juan de Alicante
Alicante
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Univesitario Torrecárdenas
Almería
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Complejo Hospitalario Universitario de Badajoz
Badajoz
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Clínic Barcelona
Barcelona
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital de Barcelona
Barcelona
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario Vall d'Hebron
Barcelona
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital de Basurto
Bilbao
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario San Pedro de Alcántara
Cáceres
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital General Universitario de Ciudad Real
Ciudad Real
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario Reina Sofía
Córdoba
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital General Virgen de la Luz
Cuenca
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario de Torrevieja
Elche, Alicante
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital General Universitario de Elche
Elche
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital de Fuenlabrada
Fuenlabrada, Madrid
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitari Dr. Josep Trueta/Institut Català D'Oncología Girona
Girona
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario de Jaén
Jaén
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital de Especialidades de Jerez de la Frontera
Jerez de la Frontera, Cádiz
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Institut Català D'Oncologia (ICO) L'Hospitalet
L'Hospitalet de Llobregat, Barcelona
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario Insular de Gran Canaria
Las Palmas de Gran Canaria
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario Lucus Augusti
Lugo
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Central de la Defensa Gómez Ulla
Madrid
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Fundación Jimenez Díaz
Madrid
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital MD Anderson Cancer Center Madrid
Madrid
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario 12 de Octubre
Madrid
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario Clínico San Carlos
Madrid
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario Gregorio Marañón
Madrid
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario Infanta Leonor
Madrid
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario La Paz
Madrid
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario la Princesa
Madrid
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario Ramón y Cajal
Madrid
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario de Móstoles
Móstoles, Madrid
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario Morales Meseguer
Murcia
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Son Espases
Palma, Balearic Islands
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Complejo Hospitalario de Navarra
Pamplona, Navarre
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Infanta Cristina
Parla, Madrid
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitari Parc Taulí
Sabadell, Barcelona
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario Infanta Sofía
San Sebastián de los Reyes
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital De Sant Joan Despi Moissès Broggi
Sant Joan Despí, Barcelona
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Complejo Hospitalario Univ. de Santiago
Santiago de Compostela, La Coruña
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Oncoavanze
Seville
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Consorcio Hospital General Universitario de Valencia
Valencia
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor, M.D.
- Recruiting
Hospital Clínico Universitario de Valencia
Valencia
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Universitari i Politècnic La Fe
Valencia
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
- Recruiting
Hospital Álvaro Cunqueiro
Vigo
A responsible person designated by the sponsor, investigacion@mfar.net
Principal investigator selected by the sponsor
About this study
Official title: Observational Epidemiological Study of Cancer-associated Thrombosis: Registry of Thrombosis & NEoplasia of SEOM (TESEO Study)
Epidemiological, observational, non-interventional, multicentric study on patients diagnosed with cancer who develop a venous or arterial thromboembolic episode, symptomatic or incidental, within a month prior to cancer diagnosis or at anytime after such diagnosis
- Conditions
- Thromboembolism, Cancer
- Medical subject headings
- Thromboembolism, Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Location of origin of the thromboembolytic event
Distribution in the number of patients according to the anatomical location affected by the thromboembolytic event.
Measured: Baseline
Vessel of origin of the thromboembolytic event
Distribution in the number of patients according to the type of vessel affected by the thromboembolytic event.
Measured: Baseline
Thromboembolytic event diagnosis type
Proportion of patients with incidental versus symptomatic thormboembolic events
Measured: Baseline
Primary tumor at the time of the thromboembolic event
Distribution of patients according to the organ affected by the primary tumor.
Measured: Baseline
Tumor-Node-Metastasis classification
Based on the American Joint Committee on Cancer 2018 Tumor-Node-Metastasis classification system: T for extent or size of the tumor, N for lymph nodes spread and M for metastasis.
Measured: Baseline
Time between cancer diagnosis and thromboembolic event
Based on date on confirmed diagnosis of cancer (primary tumor) and date of thromboembolic event
Measured: Baseline
Patient situation at the last visit
Number of patients with rethrombosis, bleeding, other complications, tumor progression or death.
Measured: 12 months
Characteristics of treatment administered for cancer
Based on the number of patients prescribed with chemotherapy, radiation therapy, hormonal therapy, erythropoietin, transfusions, surgery, catheter, etc.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2019
- Study start4 Jul 2018
- Primary completionJul 2026 (estimated)
- Study completionJul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ThromboembolismStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 700 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fundación Sociedad Española de Oncologia Médica
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Andres Muñoz, M.D., Study chair, Hospital General Universitario Gregorio Marañón, MadridJosé Muñoz Langa, M.D., Study chair, Hospital Universitario y Politécnico La Fe, ValenciaAlberto Carmona Bayonas, M.D., Study chair, Hospital Universitario Morales Meseguer, MurciaPaula Jiménez Fonseca, M.D., Study chair, Hospital Universitario Central de Asturias, OviedoPedro Pérez Segura, M.D., Study chair, Hospital Universitario Clínico San Carlos, MadridEva Martínez de Castro, M.D., Study chair, Hospital Universitario Marqués de Valdecilla, Santander
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03855592
- Sponsor's protocol ID
- SEOM-TESEO-2017-01
- Acronym
- TESEO
- Status last verified
- May 2025
- First submitted
- 19 Feb 2019
- Last updated
- 16 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 16 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observational Epidemiological Study of Cancer-associated Thrombosis: Registry of Thrombosis & NEoplasia of SEOM (TESEO Study)
- ClinicalTrials.gov ID
- NCT03855592
- Acronym / sponsor ID
- TESEO / SEOM-TESEO-2017-01
- Conditions
- Thromboembolism, Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 700 participants (estimated)
- Lead sponsor
- Fundación Sociedad Española de Oncologia MédicaUniversity, hospital or other
- Study start
- 4 Jul 2018 (actual)
- Primary completion
- Jul 2026 (estimated)
- Study completion
- Jul 2026 (estimated)
- First posted
- 27 Feb 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Epidemiological, observational, non-interventional, multicentric study on patients diagnosed with cancer who develop a venous or arterial thromboembolic episode, symptomatic or incidental, within a month prior to cancer diagnosis or at anytime after such diagnosis
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Cancer patients
Key inclusion criteria (3 listed)
- Over 18 years of age with a histologically confirmed diagnosis of malignant tumor.
- Venous or arterial thromboembolism episode, symptomatic or incidental, in the month prior or any time after the cancer diagnosis and in the three previous months to enrollment, confirmed with an imaging technique: Doppler echocardiography, computed tomography (CT) angiography, etc.
- Signing of informed consent.
Key exclusion criteria (3 listed)
- Clinical diagnosis of thromboembolic event without radiological confirmation.
- Presenting a single episode of superficial thrombophlebitis without association with another thromboembolic event.
- Each patient will be recorded just once, and therefore a second thromboembolic event will be considered a rethrombosis and will be recorded as such. Patients with a rethrombosis and a previous thromboembolic event before the start of the study in each center will not be able to be included.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Location of origin of the thromboembolytic event
Time frame: Baseline
Distribution in the number of patients according to the anatomical location affected by the thromboembolytic event.
Vessel of origin of the thromboembolytic event
Time frame: Baseline
Distribution in the number of patients according to the type of vessel affected by the thromboembolytic event.
Thromboembolytic event diagnosis type
Time frame: Baseline
Proportion of patients with incidental versus symptomatic thormboembolic events
Primary tumor at the time of the thromboembolic event
Time frame: Baseline
Distribution of patients according to the organ affected by the primary tumor.
Tumor-Node-Metastasis classification
Time frame: Baseline
Based on the American Joint Committee on Cancer 2018 Tumor-Node-Metastasis classification system: T for extent or size of the tumor, N for lymph nodes spread and M for metastasis.
Time between cancer diagnosis and thromboembolic event
Time frame: Baseline
Based on date on confirmed diagnosis of cancer (primary tumor) and date of thromboembolic event
Patient situation at the last visit
Time frame: 12 months
Number of patients with rethrombosis, bleeding, other complications, tumor progression or death.
Characteristics of treatment administered for cancer
Time frame: Baseline
Based on the number of patients prescribed with chemotherapy, radiation therapy, hormonal therapy, erythropoietin, transfusions, surgery, catheter, etc.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 May 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Thromboembolism
Not yet recruitingPhase 3
TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia
RecruitingPhase 3
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
Venous Thromboembolism (VTE)
RecruitingPhase 3
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Venous Thromboembolism (VTE)
RecruitingPhase 3
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Cancer-Associated Thrombosis (CAT)
RecruitingPhase 3
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
Symptomatic Venous Thromboembolism (VTE)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Andres Muñoz, M.D. study chair
Hospital General Universitario Gregorio Marañón, Madrid
José Muñoz Langa, M.D. study chair
Hospital Universitario y Politécnico La Fe, Valencia
Alberto Carmona Bayonas, M.D. study chair
Hospital Universitario Morales Meseguer, Murcia
48 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Thromboembolism and Cancer, run by Fundación Sociedad Española de Oncologia Médica at 48 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 48 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Andres Muñoz, M.D. (+34 93 434 44 12, investigacion@mfar.net), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Location of origin of the thromboembolytic event (time frame: Baseline). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 May 2025.